Adavosertib

Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the kinase enzyme WEE1. It is being developed by AstraZeneca. It is being investigated as a treatment for pancreatic cancer with a phase 1 trial (University of Michigan researchers are as of 2019 planning a phase 2 study. ), and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329441852 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.